Skip to content
  • About Us
    • Corporate Profile
    • Senior Management
    • Board of Directors
    • Advisors and EDBI Connect
    • Core Values
    • Focal Sectors
  • Why EDBI
    • Why EDBI
    • Impact
    • Value Creation
  • Portfolio
  • News
  • Contact Us
  • About Us
    • Corporate Profile
    • Senior Management
    • Board of Directors
    • Advisors and EDBI Connect
    • Core Values
    • Focal Sectors
  • Why EDBI
    • Why EDBI
    • Impact
    • Value Creation
  • Portfolio
  • News
  • Contact Us
  • About Us
    • Corporate Profile
    • Senior Management
    • Board of Directors
    • Advisors and EDBI Connect
    • Core Values
    • Focal Sectors
  • Why EDBI
    • Why EDBI
    • Impact
    • Value Creation
  • Portfolio
  • News
  • Contact Us
Contact us

Adamas Pharmaceuticals presents positive clinical data for ADS-5102

  • 2 October 2013

ADAMAS PHARMACEUTICALS PRESENTS POSITIVE CLINICAL DATA FOR ADS-5102, A TREATMENT FOR LEVODOPA-INDUCED DYSKINESIA, AT THE WORLD PARKINSON’S CONGRESS

Join our community!

Subscribe to our quarterly e-Newsletter, The Upside to find out what’s shaping the future industries of Singapore and the region.

Subscribe now
  • Careers
  • Terms of Use
  • Privacy
  • en
  • cn
  • English

    • English
    • Chinese

    © 2021- edbi. All rights reserved.